Two  ||| S:0 E:4 ||| CD
types  ||| S:4 E:10 ||| NNS
of  ||| S:10 E:13 ||| IN
myeloperoxidase-antineutrophil  ||| S:13 E:44 ||| JJ
cytoplasmic  ||| S:44 E:56 ||| JJ
autoantibodies  ||| S:56 E:71 ||| NN
with  ||| S:71 E:76 ||| IN
a  ||| S:76 E:78 ||| DT
high  ||| S:78 E:83 ||| JJ
affinity  ||| S:83 E:92 ||| NN
and  ||| S:92 E:96 ||| CC
a  ||| S:96 E:98 ||| DT
low  ||| S:98 E:102 ||| JJ
affinity  ||| S:102 E:111 ||| NN
in  ||| S:111 E:114 ||| IN
small  ||| S:114 E:120 ||| JJ
vessel  ||| S:120 E:127 ||| NN
vasculitis  ||| S:127 E:138 ||| VBD
Myeloperoxidase  ||| S:138 E:154 ||| NNP
( ||| S:154 E:155 ||| -LRB-
MPO ||| S:155 E:158 ||| NNP
)  ||| S:158 E:160 ||| -RRB-
-anti-neutrophil  ||| S:160 E:177 ||| FW
cytoplasmic  ||| S:177 E:189 ||| FW
autoantibodies  ||| S:189 E:204 ||| FW
( ||| S:204 E:205 ||| -LRB-
ANCAs ||| S:205 E:210 ||| NNP
)  ||| S:210 E:212 ||| -RRB-
are  ||| S:212 E:216 ||| VBP
detected  ||| S:216 E:225 ||| VBN
at  ||| S:225 E:228 ||| IN
a  ||| S:228 E:230 ||| DT
high  ||| S:230 E:235 ||| JJ
rate  ||| S:235 E:240 ||| NN
in  ||| S:240 E:243 ||| IN
microscopic  ||| S:243 E:255 ||| JJ
polyangiitis  ||| S:255 E:268 ||| NN
and  ||| S:268 E:272 ||| CC
renal-limited  ||| S:272 E:286 ||| JJ
vasculitis ||| S:286 E:296 ||| NN
.  ||| S:296 E:298 ||| .
MPO-ANCA  ||| S:298 E:307 ||| JJ
titers  ||| S:307 E:314 ||| NNS
are  ||| S:314 E:318 ||| VBP
not  ||| S:318 E:322 ||| RB
always  ||| S:322 E:329 ||| RB
reflected  ||| S:329 E:339 ||| VBN
in  ||| S:339 E:342 ||| IN
the  ||| S:342 E:346 ||| DT
disease  ||| S:346 E:354 ||| NN
activity ||| S:354 E:362 ||| NN
.  ||| S:362 E:364 ||| .
We  ||| S:364 E:367 ||| PRP
studied  ||| S:367 E:375 ||| VBD
the  ||| S:375 E:379 ||| DT
titer  ||| S:379 E:385 ||| NN
and  ||| S:385 E:389 ||| CC
affinity  ||| S:389 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
MPO-ANCA  ||| S:401 E:410 ||| JJ
in  ||| S:410 E:413 ||| IN
sera  ||| S:413 E:418 ||| NN
from  ||| S:418 E:423 ||| IN
patients  ||| S:423 E:432 ||| NNS
in  ||| S:432 E:435 ||| IN
relation  ||| S:435 E:444 ||| NN
to  ||| S:444 E:447 ||| TO
vasculitis  ||| S:447 E:458 ||| VB
activity ||| S:458 E:466 ||| NN
.  ||| S:466 E:468 ||| .
Blood  ||| S:468 E:474 ||| NN
samples  ||| S:474 E:482 ||| NNS
were  ||| S:482 E:487 ||| VBD
collected  ||| S:487 E:497 ||| VBN
from  ||| S:497 E:502 ||| IN
27  ||| S:502 E:505 ||| CD
newly  ||| S:505 E:511 ||| RB
diagnosed  ||| S:511 E:521 ||| VBN
or  ||| S:521 E:524 ||| CC
relapsed  ||| S:524 E:533 ||| JJ
patients  ||| S:533 E:542 ||| NNS
with  ||| S:542 E:547 ||| IN
MPO-ANCA-associated  ||| S:547 E:567 ||| JJ
vasculitides ||| S:567 E:579 ||| NN
.  ||| S:579 E:581 ||| .
The  ||| S:581 E:585 ||| DT
MPO-ANCA  ||| S:585 E:594 ||| JJ
titer  ||| S:594 E:600 ||| NN
was  ||| S:600 E:604 ||| VBD
determined  ||| S:604 E:615 ||| VBN
by  ||| S:615 E:618 ||| IN
a  ||| S:618 E:620 ||| DT
direct  ||| S:620 E:627 ||| JJ
enzyme-linked  ||| S:627 E:641 ||| JJ
immunosorbent  ||| S:641 E:655 ||| JJ
assay  ||| S:655 E:661 ||| NNS
( ||| S:661 E:662 ||| -LRB-
ELISA ||| S:662 E:667 ||| NNP
)  ||| S:667 E:669 ||| -RRB-
using  ||| S:669 E:675 ||| VBG
homogeneously  ||| S:675 E:689 ||| JJ
purified  ||| S:689 E:698 ||| JJ
human  ||| S:698 E:704 ||| JJ
MPO  ||| S:704 E:708 ||| NN
of  ||| S:708 E:711 ||| IN
leukocytes ||| S:711 E:721 ||| NN
.  ||| S:721 E:723 ||| .
The  ||| S:723 E:727 ||| DT
MPO-ANCA  ||| S:727 E:736 ||| JJ
affinity  ||| S:736 E:745 ||| NN
was  ||| S:745 E:749 ||| VBD
expressed  ||| S:749 E:759 ||| VBN
as  ||| S:759 E:762 ||| IN
IC50  ||| S:762 E:767 ||| NNP
that  ||| S:767 E:772 ||| WDT
was  ||| S:772 E:776 ||| VBD
determined  ||| S:776 E:787 ||| VBN
by  ||| S:787 E:790 ||| IN
a  ||| S:790 E:792 ||| DT
competitive  ||| S:792 E:804 ||| JJ
inhibition  ||| S:804 E:815 ||| JJ
method  ||| S:815 E:822 ||| NN
using  ||| S:822 E:828 ||| VBG
the  ||| S:828 E:832 ||| DT
ELISA ||| S:832 E:837 ||| NNP
.  ||| S:837 E:839 ||| .
The  ||| S:839 E:843 ||| DT
MPO-ANCA  ||| S:843 E:852 ||| JJ
affinity  ||| S:852 E:861 ||| NN
of  ||| S:861 E:864 ||| IN
27  ||| S:864 E:867 ||| CD
sera  ||| S:867 E:872 ||| NN
from  ||| S:872 E:877 ||| IN
27  ||| S:877 E:880 ||| CD
patients  ||| S:880 E:889 ||| NNS
could  ||| S:889 E:895 ||| MD
be  ||| S:895 E:898 ||| VB
classified  ||| S:898 E:909 ||| VBN
into  ||| S:909 E:914 ||| IN
a  ||| S:914 E:916 ||| DT
high-affinity  ||| S:916 E:930 ||| JJ
type  ||| S:930 E:935 ||| NN
( ||| S:935 E:936 ||| -LRB-
14  ||| S:936 E:939 ||| CD
sera ||| S:939 E:943 ||| CD
)  ||| S:943 E:945 ||| -RRB-
and  ||| S:945 E:949 ||| CC
a  ||| S:949 E:951 ||| DT
low-affinity  ||| S:951 E:964 ||| JJ
type  ||| S:964 E:969 ||| NN
( ||| S:969 E:970 ||| -LRB-
13  ||| S:970 E:973 ||| CD
sera ||| S:973 E:977 ||| CD
) ||| S:977 E:978 ||| -RRB-
.  ||| S:978 E:980 ||| .
The  ||| S:980 E:984 ||| DT
mean  ||| S:984 E:989 ||| JJ
values  ||| S:989 E:996 ||| NNS
for  ||| S:996 E:1000 ||| IN
IC50  ||| S:1000 E:1005 ||| CD
in  ||| S:1005 E:1008 ||| IN
the  ||| S:1008 E:1012 ||| DT
two  ||| S:1012 E:1016 ||| CD
types  ||| S:1016 E:1022 ||| NNS
were  ||| S:1022 E:1027 ||| VBD
0.15+ ||| S:1027 E:1032 ||| CD
/ ||| S:1032 E:1033 ||| CD
-0.06  ||| S:1033 E:1039 ||| CD
microg ||| S:1039 E:1045 ||| CD
/ ||| S:1045 E:1046 ||| CD
ml  ||| S:1046 E:1049 ||| NNS
and  ||| S:1049 E:1053 ||| CC
0.54+ ||| S:1053 E:1058 ||| FW
/ ||| S:1058 E:1059 ||| FW
-0.15  ||| S:1059 E:1065 ||| FW
microg ||| S:1065 E:1071 ||| FW
/ ||| S:1071 E:1072 ||| FW
ml ||| S:1072 E:1074 ||| FW
,  ||| S:1074 E:1076 ||| ,
and  ||| S:1076 E:1080 ||| CC
the  ||| S:1080 E:1084 ||| DT
difference  ||| S:1084 E:1095 ||| NN
was  ||| S:1095 E:1099 ||| VBD
statistically  ||| S:1099 E:1113 ||| RB
significant  ||| S:1113 E:1125 ||| JJ
( ||| S:1125 E:1126 ||| -LRB-
p  ||| S:1126 E:1127 ||| FW
< ||| S:1127 E:1128 ||| SYM
0.0000000684 ||| S:1128 E:1140 ||| FW
) ||| S:1140 E:1141 ||| -RRB-
.  ||| S:1141 E:1143 ||| .
Between  ||| S:1143 E:1151 ||| IN
the  ||| S:1151 E:1155 ||| DT
two  ||| S:1155 E:1159 ||| CD
groups  ||| S:1159 E:1166 ||| NNS
of  ||| S:1166 E:1169 ||| IN
patients  ||| S:1169 E:1178 ||| NNS
divided  ||| S:1178 E:1186 ||| VBN
by  ||| S:1186 E:1189 ||| IN
the  ||| S:1189 E:1193 ||| DT
affinity ||| S:1193 E:1201 ||| NN
,  ||| S:1201 E:1203 ||| ,
there  ||| S:1203 E:1209 ||| EX
were  ||| S:1209 E:1214 ||| VBD
differences  ||| S:1214 E:1226 ||| NNS
in  ||| S:1226 E:1229 ||| IN
the  ||| S:1229 E:1233 ||| DT
Birmingham  ||| S:1233 E:1244 ||| NNP
Vasculitis  ||| S:1244 E:1255 ||| NNP
Activity  ||| S:1255 E:1264 ||| NNP
Score  ||| S:1264 E:1270 ||| NNP
( ||| S:1270 E:1271 ||| -LRB-
BVAS ||| S:1271 E:1275 ||| NNP
) ||| S:1275 E:1276 ||| -RRB-
:  ||| S:1276 E:1278 ||| :
and  ||| S:1278 E:1282 ||| CC
in  ||| S:1282 E:1285 ||| IN
C-reactive  ||| S:1285 E:1296 ||| JJ
protein  ||| S:1296 E:1304 ||| NN
( ||| S:1304 E:1305 ||| -LRB-
CRP ||| S:1305 E:1308 ||| NNP
) ||| S:1308 E:1309 ||| -RRB-
:  ||| S:1309 E:1311 ||| :
( ||| S:1311 E:1312 ||| -LRB-
p  ||| S:1312 E:1313 ||| FW
< ||| S:1313 E:1314 ||| SYM
0.00093  ||| S:1314 E:1322 ||| FW
and  ||| S:1322 E:1326 ||| CC
p  ||| S:1326 E:1327 ||| CD
< ||| S:1327 E:1328 ||| SYM
0.00129 ||| S:1328 E:1335 ||| CD
,  ||| S:1335 E:1337 ||| ,
respectively ||| S:1337 E:1349 ||| RB
) ||| S:1349 E:1350 ||| -RRB-
.  ||| S:1350 E:1352 ||| .
However ||| S:1352 E:1359 ||| RB
,  ||| S:1359 E:1361 ||| ,
the  ||| S:1361 E:1365 ||| DT
difference  ||| S:1365 E:1376 ||| NN
in  ||| S:1376 E:1379 ||| IN
titer  ||| S:1379 E:1385 ||| NN
was  ||| S:1385 E:1389 ||| VBD
not  ||| S:1389 E:1393 ||| RB
statistically  ||| S:1393 E:1407 ||| RB
significant  ||| S:1407 E:1419 ||| JJ
( ||| S:1419 E:1420 ||| -LRB-
p  ||| S:1420 E:1421 ||| FW
< ||| S:1421 E:1422 ||| SYM
0.0265 ||| S:1422 E:1428 ||| FW
) ||| S:1428 E:1429 ||| -RRB-
.  ||| S:1429 E:1431 ||| .
The  ||| S:1431 E:1435 ||| DT
affinity  ||| S:1435 E:1444 ||| NN
remained  ||| S:1444 E:1453 ||| VBD
steady  ||| S:1453 E:1460 ||| JJ
from  ||| S:1460 E:1465 ||| IN
the  ||| S:1465 E:1469 ||| DT
disease  ||| S:1469 E:1477 ||| NN
onset  ||| S:1477 E:1483 ||| NN
to  ||| S:1483 E:1486 ||| TO
remission  ||| S:1486 E:1496 ||| VB
or  ||| S:1496 E:1499 ||| CC
relapse ||| S:1499 E:1506 ||| NN
.  ||| S:1506 E:1508 ||| .
The  ||| S:1508 E:1512 ||| DT
affinity  ||| S:1512 E:1521 ||| NN
of  ||| S:1521 E:1524 ||| IN
MPO-ANCA  ||| S:1524 E:1533 ||| JJ
from  ||| S:1533 E:1538 ||| IN
patients  ||| S:1538 E:1547 ||| NNS
with  ||| S:1547 E:1552 ||| IN
MPO-ANCA-associated  ||| S:1552 E:1572 ||| JJ
vasculitides  ||| S:1572 E:1585 ||| NN
were  ||| S:1585 E:1590 ||| VBD
largely  ||| S:1590 E:1598 ||| RB
distinguished  ||| S:1598 E:1612 ||| VBN
into  ||| S:1612 E:1617 ||| IN
a  ||| S:1617 E:1619 ||| DT
high  ||| S:1619 E:1624 ||| JJ
and  ||| S:1624 E:1628 ||| CC
a  ||| S:1628 E:1630 ||| DT
low  ||| S:1630 E:1634 ||| JJ
affinity ||| S:1634 E:1642 ||| NN
,  ||| S:1642 E:1644 ||| ,
irrespective  ||| S:1644 E:1657 ||| RB
of  ||| S:1657 E:1660 ||| IN
the  ||| S:1660 E:1664 ||| DT
level  ||| S:1664 E:1670 ||| NN
of  ||| S:1670 E:1673 ||| IN
MPO-ANCA  ||| S:1673 E:1682 ||| JJ
titers ||| S:1682 E:1688 ||| NN
,  ||| S:1688 E:1690 ||| ,
and  ||| S:1690 E:1694 ||| CC
may  ||| S:1694 E:1698 ||| MD
be  ||| S:1698 E:1701 ||| VB
helpful  ||| S:1701 E:1709 ||| JJ
for  ||| S:1709 E:1713 ||| IN
assessment  ||| S:1713 E:1724 ||| NN
of  ||| S:1724 E:1727 ||| IN
vasculitis  ||| S:1727 E:1738 ||| JJ
activity  ||| S:1738 E:1747 ||| NN
affecting  ||| S:1747 E:1757 ||| VBG
mainly  ||| S:1757 E:1764 ||| RB
the  ||| S:1764 E:1768 ||| DT
kidney  ||| S:1768 E:1775 ||| NN
and  ||| S:1775 E:1779 ||| CC
the  ||| S:1779 E:1783 ||| DT
lung ||| S:1783 E:1787 ||| NN
.  ||| S:1787 E:1789 ||| .
